Natural Killer Cell-dependent Suppression of Systemic Spread of Human Lung Adenocarcinoma Cells by Monocyte Chemoattractant Protein-1 Gene Transfection in Severe Combined Immunodeficient Mice

Hiroshi Nokihara, Hiroaki Yanagawa, Yasuhiko Nishioka, Seiji Yano, Naofumi Mukaida, Kouji Matsushima, and Saburo Sone

Third Department of Internal Medicine, University of Tokushima School of Medicine, Tokushima 770-8503 [H. N., H. Y., Y. N., S. Y., S. S.]; Department of Molecular Oncology, Cancer Research Institute, Kanazawa University, Kanazawa 920-0934 [N. M.]; and Department of Molecular Preventive Medicine, Graduate School of Medicine, University of Tokyo, Tokyo 113-0033 [R. M.]. Japan

ABSTRACT

Monocyte chemoattractant protein-1 (MCP-1) is a chemokine with various biological activities, including augmentation of cytotoxic activity of monocytes and natural killer (NK) cells. The present study was undertaken to determine whether transfection of the MCP-1 gene into lung cancer cells affected their tumorigenicity and metastatic potential by the NK cell-mediated mechanism. The human MCP-1 gene inserted into an expression vector (BCMGSNeo) was transfected into human lung adenocarcinoma (PC-14) cells. There was no difference in in vitro proliferation between MCP-1 gene-transfected PC-14 cells and the parent cells or mock-transfected cells. The tumorigenicity and size of tumor of MCP-1 gene-transfected PC-14 cells were similar to those of the parent cells or mock-transfected cells when tumor cells were injected into the s.c. space of NK cell-intact SCID mice. Decreased survival of these mice and metastasis by a NK cell-mediated mechanism, depending on organ microenvironment.

INTRODUCTION

MCP-1, also known as MCAF, is a member of the CC (or β) chemokine family of cytokines (1) and has been reported as a selective chemoattractant protein for monocytes but not for neutrophils (2, 3). It stimulates the cytotoxic activity of monocytes and enhances the expression of adhesion molecules, such as CD11b and CD11c. In addition to the activation of monocyte functions, the enhancing activity of NK cells by MCP-1 on cytotoxicity and migration has been reported (4–7). Transfection of cytokine genes into tumor cells has been investigated widely for analysis of cytokine-mediated biological effects on tumor growth and is very important in successful cancer immunotherapy to attract effector cells such as monocyte-macrophages and lymphocytes into the tumor growth site (8, 9). Therefore, we examined the effect of MCP-1 gene transfection on tumor progression. Our recent reports (10, 11) demonstrated that MCP-1 gene transfection into a small human cell lung cancer cell line (H69/VP) did not affect tumorigenicity or growth rates in the s.c. space of nude mice or SCID mice, although it caused greater macrophage infiltration into the tumors. Moreover, to evaluate the monocyte-mediated effect of MCP-1 more selectively, we used NK cell-depleted SCID mice pretreated with anti-IL-2 receptor β chain Ab (TM-B1) and showed that MCP-1 gene transfection into H69/VP cells again had no effect on metastasis formation in NK cell-depleted SCID mice (11). However, MCP-1 gene transfection into H69/VP cells caused a remarkable enhancement of Ab-dependent cellular cytotoxicity reaction by augmentation of macrophage infiltration into metastatic lesions and hence augmented the therapeutic efficacy of anti-P-glycoprotein Ab on metastasis by P-glycoprotein-expressing H69/VP cells in multiple organs such as the liver, kidneys, and systemic lymph nodes (11).

On the other hand, the NK cell-mediated effect of MCP-1 on metastasis has not been examined thus far. We developed a model for lung metastasis and PFs of human lung adenocarcinoma cells in NK cell-intact SCID mice (12). To directly analyze the contribution of NK cells, we examined the metastatic potential of MCP-1 gene-transfected lung adenocarcinoma cells in NK cell-intact and NK cell-depleted SCID mice in this study.

MATERIALS AND METHODS

Reagents. FBS and G418 were purchased from Life Technologies (Rockville, MD). Recombinant human MCP-1 was produced in a murine myeloma cell line, X5563, transfected with cDNA for human MCP-1, and purified to homogeneity by carboxymethyl high-performance liquid chromatography (13). Recombinant human IL-2 (specific activity, 1.14 × 10^7 units/mg protein as assayed on IL-2-dependent murine NK cells) was a gift from Takeda Pharmaceutical Co. (Osaka, Japan). None of these materials contained endotoxins, as judged by Limulus amebocyte assay (Seikagaku Kogyo, Tokyo, Japan). [3H]IdUrd (specific activity, 5 Ci/mg) was purchased from Amer sham Pharmacia Biotech (Buckinghamshire, England).

Cell Cultures. Human lung adenocarcinoma PC-14 cells were kindly supplied by Dr. N. Saijo (National Cancer Institute, Tokyo, Japan), and K562 cells were obtained from the American Type Culture Collection (Rockville, MD). These cell cultures were maintained in RPMI 1640 supplemented with 10% heat-inactivated FBS (CRPMI 1640) and gentamicin at 37°C in a humidified atmosphere of 5% CO_2 in air. YAC-1 cells were generously given by W. Chambers (University of Pittsburgh, Pittsburgh, PA) and were maintained in CRPMI 1640 and 2 mM glutamine, 100 µg/ml streptomycin, 100 IU/ml penicillin, and 5 × 10^{-5} M 2-mercaptoethanol (Life Technologies) at 37°C in a humidified atmosphere of 5% CO_2 in air.

Gene Transfection and Cloning of Transfected Cell Lines. PC-14 cells were transfected with BCMGSNeoMCAF (13) containing a 400-bp Pol fragment of human MCP-1 cDNA using Lipofectin Reagents (Life Technologies), as described in detail elsewhere (14). After 18 h, the medium was changed to...
fresh CRPM I 1640 medium containing 800 μg/ml of G418 in 24-well plates. Cell
clones resistant to G418 were assayed for the expression of MCP-1 mRNA
by Northern blotting. For the establishment of cell lines that stably
expressed MCP-1, the subclones positive for MCP-1 mRNA were cloned by
a similar method.

Preparation of Total Cellular RNA and Northern Blot Analysis. Tumor
cells were lysed in ISOGEN (Nippon Gene, Tokyo, Japan), a mixture of
guanidinium isothiocyanate and phenol. Total cellular RNA was then
extracted with chloroform and precipitated with isopropanol, as described
elsewhere (11). The denatured RNA (5 μg) was electrophoresed in a 1% agarose gel containing 2.2 M formaldehyde, transferred to a Hybond-N
nylon membrane, and hybridized with 32P-labeled probes. The filters were
washed twice with 0.1X saline sodium phosphate-EDTA and 0.1% SDS
for 1 h at 60°C. The membranes were autoradiographed using a Fujix
bioimaging analyzer BAS 1500 (Fuji Photofilm Co., Tokyo, Japan).

Washing Procedure. The membranes were washed twice with 0.1
washed three times and incubated with 100 μl of rabbit antihuman MCP-1
were then incubated in the wells overnight at 4°C. The wells were then
washed three times with PBS containing 0.05% Tween 20 (buffer
A). The standards and samples diluted in buffer were then washed three times with PBS containing 0.05% Tween 20 (buffer
A). The standards and samples diluted in buffer were added to each well, and the plates were incubated at room temperature for
30 min. The enzyme reaction was stopped by adding 100 μl of rabbit antihuman MCP-1 Ab at 37°C for 2 h. They were then washed at least 10 times and incubated with 100 μl of alkaline phosphate-conjugated antibiot IgG (Tago code 6500);
diluted 1:10,000 with buffer B) at 37°C for 2 h. Finally, 100 μl of enzyme
substrate solution [1 mg/ml p-nitrophenylphosphate (Sigma Chemical Co., St.
Louis, MO) in 1 M diethanolamine (pH 9.8) supplemented with 0.5 mM MgCl2] were added to each well, and the plates were incubated at room temperature for
30 min. The enzyme reaction was stopped by adding 100 μl 1 M NaOH, and
A405 was determined using an ELISA plate reader (Titertek Multiscan; Flow,
Meckenheim, Germany). All samples were assayed in triplicate at least.

Analysis by Flow Cytometry. Expression of surface antigens was meas-
ured by flow microfluorometry as described in detail previously (11). Briefly,
tumor cells (1×105) were washed once with PBS supplemented with 2% FBS
and 0.05% sodium azide (2% FBS-PBS). The washed cells were incubated for
30 min at 4°C in 2% FBS-PBS with anti-CD44 (Cosmo Bio Co., Tokyo,
Japan), anti-MHC class I (Immunotech, Marseilles, France), anti-ICAM-1 Abs
(Becton Dickinson, San Jose, CA), or normal mouse serum as a negative
control. They were then washed twice with 2% FBS-PBS and treated with
FITC-conjugated goat antimouse IgG (H+L; Immunotech) for 30 min at 4°C.
The cells were washed again, and their fluorescence intensity was measured
with a FACSScan (Becton Dickinson, Mountain View, CA).

In Vitro Proliferation Assays. Tumor cells (1×105) were plated into each
well of six-well plates. After 12, 24, 48, 72, and 96 h incubation at 37°C, the
cells were trypsinized, and the number of viable cells was counted using trypan
blue stain (Life Technologies). Triplicate wells were counted per time point.
Cell proliferation was estimated as the doubling time.

Animals. Male SCID mice, 6–8 weeks of age, were obtained from Charles
River (Yokohama, Japan) and maintained under specific pathogen-free con-
tions. Experiments were performed according to the guidelines of our uni-
versity (University of Tokushima).

Tumorigenicity and Experimental Metastasis. For the production of
tumors, parental PC-14 and PC-14 clones transfected with the MCP-1 gene of
Neo gene (5×106 cells/200 μl PBS/mouse) were injected i.c. into the flanks of
SCID mice. The formation and size of the tumors were monitored every 3–4
days until day 49. Tumor volume (V) was calculated by the formula V = 4/3πr3,
where r is the shortest diameter and d is the shortest diameter of the tumor.

For experimental metastases of human lung cancer cells, viable tumor cells
suspended in 300 μl of PBS were injected into the lateral tail vein of SCID
mice (12, 16). In some experiments, SCID mice received injections i.p. with
TM-β1 Ab (1 mg/mouse) 2 days before tumor inoculation to deplete NK cells
(16). After the indicated periods, the mice were sacrificed, and the numbers of
metastatic lymph nodes were counted. Nodules in the liver, kidneys, and lungs
were counted with the aid of a dissecting microscope.

Isolation of Human CD56+ NK Cells. Leukocyte concentrates from
healthy donors were separated into peripheral blood mononuclear cells by
density gradient centrifugation in lymphocyte separation medium (10). Sub-
sequently, peripheral blood mononuclear cells were separated into lympho-
cytes and monocytes by counterflow centrifugal elutriation in a Beckman
JE-5.0 rotor (Beckman Instruments, Inc., Fullerton, CA) as reported previously
(10). The lymphocyte-rich fraction was collected at flow rates of 12–16 ml/min
at 2000 rpm. The purity of the lymphocyte fraction, determined by morpho-
logical examination and nonspecific esterase staining, was >99%. In these
lymphocytes, highly purified CD56+ cells were obtained by MACS (Miltenyi
Biotec, Bergisch Gladbach, Germany) according to the manufacturer’s instruc-
tions as described previously (17). Briefly, the purified lymphocytes were
incubated with MACS CD56 MicroBeads on ice for 15 min. After washing,
these cells were applied for the positive selection column MiniMACS MS/i
RS+150. The column was washed five times, and CD56+ cells were flushed out.
The purity of CD56+ NK cells was >94%, as determined by flow cytometry
after staining with PE-conjugated antihuman CD56+ Ab (Immunotech).

The Cytotoxicity Assay. As effector cells, the spleen cells of SCID mice
were also prepared as described elsewhere (18). The purified human CD56+ NK
cells or murine spleen cells were cultured in medium with various concen-
trations of rMCP-1, IL-2 (500 units/ml), or culture supernatants of tumor
of PC-14neo13 or PC-14MCP2 cells. The cytotoxicity was determined using a standard
125I release assay as described previously (10). The K562, YAC-1, or PC-14 cells were used as targets to evaluate NK activity. In brief,
target cells were labeled with 100 μCi of 125I for 1 h. After washing twice,
these effector and target cells were plated at an appropriate E:T ratio in 96-well
round-bottomed plates. The supernatant (100 μl) was collected after a 4-h
(human CD56+ NK cells) or an 8-h (murine spleen cells) incubation, and the
radioactivity was counted using a gamma counter. Determinations were carried
out in triplicate. The percentage of specific cytolyis was calculated from the
release of 125I from test samples and control samples, as follows:

% specific lysis = \frac{(E - S)}{(M - S)} \times 100

in which E is the release in the test sample (cpm in the supernatant from target
cells incubated with test effector cells), S is the spontaneous release (cpm in
the supernatant from target cells incubated in medium alone), and M is the
maximum release (cpm released from target cells lysed with 1 nHCl).

Distribution and Fate of [3H]IdUrd-labeled Tumor Cells in Vivo. To
investigate the distribution and fate of mock-transfected cells or MCP-1
transfected cells, we compared the organ distribution of these cells after
fate injection with a method reported earlier (19). In brief, cells were labeled
with [3H]IdUrd for 24 h. After washing twice, [3H]IdUrd-labeled cells
(1×106 cells/300 μl of PBS/mouse) were injected into the lateral tail vein of
SCID mice. After the indicated periods, the mice were sacrificed, and the
radioactivity of each organ was counted using a gamma counter.

Statistical Analysis. The significance of differences of in vitro data were
analyzed by Student’s t test (two-tailed), and the significance of differences of
in vivo data were analyzed by Mann-Whitney U test or Wilcoxon test.

RESULTS

Transfer of the MCP-1 Gene to Human Lung Adenocarcinoma
Cells. In the first set of experiments, we examined whether parental
PC-14 cells produced endogenous human MCP-1 (Fig. 1; Table 1). We
found no production of MCP-1 at mRNA or protein level in
parental PC-14 cells. After transfection with BCMGMSNeoMCAF or
BCMMSNeo, we selected three clones that produce MCP-1 (PC-
14MCP2, PC-14MCP10, and PC-14MCP12) and two neo control clones
(PC-14neo7 and PC-14neo13) for the following assays (Fig. 1). These transfectants (PC-14MCP2, PC-14MCP10, and PC-14MCP12)
secreted MCP-1 stably for at least 15 months in vitro. Transfection of the MCP-1 gene into PC-14 cells did not cause any change in the expression of surface antigens (MHC class I, CD44, and ICAM-1) or in vitro proliferation (Table 1). Moreover, we examined production of other cytokines, such as IL-1, IL-6, IL-8, granulocyte-CSF, granulocyte/macrophage-CSF, macrophage-CSF, tumor necrosis factor-α, IFN-γ, or VEGF. PC-14 cells or transfectants produced IL-6, IL-8, M-CSF, and VEGF, and there was no difference in production of these cytokines (data not shown).

Tumorigenicity and in vivo Growth of MCP-1 Gene-transfected Human Lung Adenocarcinoma Cells in NK Cell-intact SCID Mice. To evaluate the effect of MCP-1 production on tumorigenicity and in vivo growth, we inoculated parental, neo control, and MCP-1 gene-transfected PC-14 cells (5 × 10⁶ cells) s.c. into the flank of SCID mice and measured tumor diameters every 3–4 days until day 42. All seven cell lines tested showed 90–100% tumor uptake on day 42, irrespective of MCP-1 production (Table 1). There was no significant difference statistically in the in vivo growth rate between parental tumors and transfectants (Fig. 2).

Metastasis of MCP-1 Gene-transfected Human Lung Adenocarcinoma Cells in NK Cell-intact SCID Mice. We established previously (12) a model of lung metastasis and malignant PE by PC-14 cells in NK cell-intact SCID mice. Next, we examined the metastatic potential of MCP-1 gene-transfected PC-14 cells in this model. PC-14 cells with or without MCP-1 gene transfection (1 × 10⁶) were inoculated i.v. into SCID mice, and the mice were sacrificed on day 56. Parent and neo control cells formed numerous metastases mainly in the lungs, and a high incidence in the formation of PE was observed (Table 2). In contrast, MCP-1 gene transfectants formed fewer lung metastases, and the incidence in the formation of PE was remarkably less.

Metastasis of MCP-1 Gene-transfected Human Lung Adenocarcinoma Cells in NK Cell-depleted SCID Mice. To directly analyze the possible contribution of NK cells in the antimetastatic effect of MCP-1 gene transfection to PC-14 cells, PC-14 cells with or without MCP-1 gene transfection were injected i.v. into NK cell-depleted SCID mice (pretreated with TM-β1 Ab; Refs. 16 and 20). Parent and neo control cells formed numerous metastases in the liver and kidneys as well as in the lungs, which indicated that NK cell depletion facilitated metastasis formation into multiple organs by PC-14 cells consistent with previous report (12). Under the same experimental conditions, no significant differences between parent or neo control cells and MCP-1 gene transfectants were observed in metastatic formation (Table 3), which suggests that NK cells play a critical role in metastatic formation by MCP-1 gene transfectants.

Effect of MCP-1 Gene Transfection on Survival of NK Cell-intact SCID Mice Inoculated with Tumor Cells. We examined the effect of MCP-1 gene transfection on the survival of NK cell-intact mice.
Materials and Methods.

Metastatic colonies were counted as described in “Materials and Methods.”

PC-14 cells was 73.2% or 26.4%, respectively.

Spleen cells cultured with recombinant human IL-2 against YAC-1 or PC-14 cells (Fig. 5). The cytotoxicity of murine spleen cells, which suggests that the antimetastatic effect of MCP-1 gene transfectants on viability in the lungs up to 72 h after tumor cell injection. In contrast, a marked difference in cell viability in the lung was observed at 24 and 72 h after tumor cell injection in NK cell-intact SCID mice. The viability of MCP-1 gene transfectants in the lung was much lower than that of neo control cells in NK cell-intact SCID mice.

**DISCUSSION**

In the present study, we demonstrated that MCP-1 gene transfection into human lung adenocarcinoma (PC-14) cells suppressed metastatic spread in NK cell-intact SCID mice but not in NK cell-depleted SCID mice. MCP-1 produced by MCP-1 gene transfectants significantly augmented the cytotoxic activity of human NK cells and murine spleen cells, which suggests that the antimetastatic effect of MCP-1 gene transfection is mediated predominantly by the activation of NK cells with MCP-1 secreted by tumor cells.

Because lymphocytes (T and B cells) are lacking in SCID mice, NK cells in NK cell-depleted SCID mice compared with neo control cells in SCID mice with or without NK cell depletion. For this purpose, radiolabeled neo control cells or MCP-1 gene transfectants were injected i.v. into NK cell-intact or -depleted SCID mice, and the percentage of [125I]IUradiolabeled tumor cells in various organs (including the lungs) was determined as described in “Materials and Methods.” Neo control cells and MCP-1 gene transfectants were distributed equally to the lung by 4 h after tumor cell injection, irrespective of NK cell depletion from SCID mice (Table 4). However, at 24 h after tumor cell injection, six times more viable neo control cells were detected in the lungs of NK cell-depleted SCID mice compared with NK cell-intact SCID mice, which suggests that NK cells play an important role in tumor cell eradication at this phase. In NK cell-depleted SCID mice, there was no difference between neo control cells and MCP-1 gene transfectants in the lungs up to 72 h after tumor cell injection. The viability of MCP-1 gene transfectants in the lung was much lower than that of neo control cells in NK cell-intact SCID mice.

**Table 2** Metastatic formation of MCP-1 gene-transfected human lung adenocarcinoma cells in NK cell-intact SCID mice*

<table>
<thead>
<tr>
<th>Cell line</th>
<th>No. of metastatic colonies (mean ± SD)</th>
<th>Incidence of PE (mice with PE/total)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Experiment 1</td>
<td>Liver</td>
<td>Kidneys</td>
</tr>
<tr>
<td>PC-14</td>
<td>7 ± 4</td>
<td>8 ± 2</td>
</tr>
<tr>
<td>PC-14neo7</td>
<td>5 ± 3</td>
<td>9 ± 3</td>
</tr>
<tr>
<td>PC-14neo13</td>
<td>8 ± 6</td>
<td>8 ± 2</td>
</tr>
<tr>
<td>PC-14MCP2</td>
<td>5 ± 2</td>
<td>7 ± 3</td>
</tr>
<tr>
<td>PC-14MCP10</td>
<td>7 ± 4</td>
<td>10 ± 4</td>
</tr>
<tr>
<td>PC-14MCP12</td>
<td>6 ± 3</td>
<td>8 ± 2</td>
</tr>
<tr>
<td>Experiment 2</td>
<td>Liver</td>
<td>Kidneys</td>
</tr>
<tr>
<td>PC-14</td>
<td>5 ± 2</td>
<td>8 ± 3</td>
</tr>
<tr>
<td>PC-14neo13</td>
<td>8 ± 4</td>
<td>9 ± 2</td>
</tr>
<tr>
<td>PC-14MCP2</td>
<td>5 ± 4</td>
<td>10 ± 4</td>
</tr>
<tr>
<td>PC-14MCP10</td>
<td>5 ± 2</td>
<td>7 ± 3</td>
</tr>
</tbody>
</table>

* SCID mice received injections i.v. with PC-14 or PC-14 variant cells (1 × 10⁶) on day 0 and were sacrificed on day 56. Metastatic colonies were counted as described in “Materials and Methods.”

**Table 3** Metastatic formation of MCP-1 gene-transfected human lung adenocarcinoma cells in NK cell-depleted SCID mice*

<table>
<thead>
<tr>
<th>Cell line</th>
<th>Number of metastatic colonies (mean ± SD)</th>
<th>Incidence of PE (mice with PE/total)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Experiment 1</td>
<td>Liver</td>
<td>Kidneys</td>
</tr>
<tr>
<td>PC-14</td>
<td>7 ± 4</td>
<td>8 ± 2</td>
</tr>
<tr>
<td>PC-14neo7</td>
<td>5 ± 3</td>
<td>9 ± 3</td>
</tr>
<tr>
<td>PC-14neo13</td>
<td>8 ± 6</td>
<td>8 ± 2</td>
</tr>
<tr>
<td>PC-14MCP2</td>
<td>5 ± 2</td>
<td>7 ± 3</td>
</tr>
<tr>
<td>PC-14MCP10</td>
<td>7 ± 4</td>
<td>10 ± 4</td>
</tr>
<tr>
<td>PC-14MCP12</td>
<td>6 ± 3</td>
<td>8 ± 2</td>
</tr>
<tr>
<td>Experiment 2</td>
<td>Liver</td>
<td>Kidneys</td>
</tr>
<tr>
<td>PC-14</td>
<td>5 ± 2</td>
<td>8 ± 3</td>
</tr>
<tr>
<td>PC-14neo13</td>
<td>8 ± 4</td>
<td>9 ± 2</td>
</tr>
<tr>
<td>PC-14MCP2</td>
<td>5 ± 4</td>
<td>10 ± 4</td>
</tr>
<tr>
<td>PC-14MCP10</td>
<td>5 ± 2</td>
<td>7 ± 3</td>
</tr>
</tbody>
</table>

* SCID mice were pretreated with TM-β1 Ab (1 mg) for NK cell depletion and received injections i.v. with 1 × 10⁶ cells of PC-14 cells or PC-14 variant cell lines on day 0 and were sacrificed on day 21. Metastatic colonies were counted as described in “Materials and Methods.”
cells or monocyte-macrophages can be considered as mechanisms of the antimetastatic effect observed in SCID mice. NK cells, especially, have been reported to play an important role in metastasis formation (22). We demonstrated previously that NK cell depletion promoted metastasis formation by human lung cancer cell lines (H69/VP small cell carcinoma and RERF-LC-AI squamous cell carcinoma) into multiple organs, and we extended this phenomenon using PC-14 adenocarcinoma cells in this study. To deplete NK cells, we pretreated SCID mice with an i.p. injection of antimouse IL-2 receptor \(\beta\) chain Ab TM-\(\beta\)1. This treatment successfully and selectively depletes NK cells in SCID mice at least for 6 weeks, irrespective of tumor cell injection (16, 23).

Although MCP-1 was discovered originally as a chemotactic and activating factor for monocytes, the chemotactic activity of MCP-1 for T lymphocytes was documented later. In addition, recent reports (4–7) have shown that CC chemokines, including MCP-1, potentiate the function of NK cells. Loetscher et al. (6) found that CC chemokines induced chemotaxis, Ca\(^{2+}\) changes, and the release of granule enzymes from both cloned and blood NK cells. Consistent with these reports, we show in this study that MCP-1 enhanced the killer activity of human CD56\(^+\) NK cells or spleen cells of SCID mice against K562, YAC-1, or PC-14 cells in vitro. Moreover, MCP-1 gene transfection into PC-14 cells resulted in inhibition of lung metastasis only in NK cell-intact SCID mice but not in NK cell-depleted SCID mice. MCP-1 was reported to augment not only killer activity of NK cells but also migration of NK cells (4–7). These findings strongly suggest that MCP-1 secreted by transfectants augments the migration and killer activity of NK cells, hence inhibiting the lung metastasis of PC-14 cells.

The process of metastasis consists of several sequentially linked steps (24). Although tumor cells bypassed the initial steps of metastasis (separation from the primary tumor, invasion, and release into blood vessels) in our experimental metastasis model, all subsequent steps (arrest at a distant site, extravasation, and proliferation as a secondary colony with neovascularization) must have occurred. To clarify further the mechanism of inhibition of lung metastasis of MCP-1 gene transfectants in NK cell-intact SCID mice, we determined at which steps this inhibition occurred. Our results show that MCP-1 gene transfectants and neo control cells were equally arrested at the capillary of the lung at 4 h after tumor cell injection and that a marked difference in cell viability between the transfectants and neo control was observed at 24–72 h after injection. Within 6 h after injection, extravasation can occur from the capillary plexus (25), although it was not determined when PC-14 cells extravasated in this model. Therefore, it is possible that NK cells activated with MCP-1 secreted by transfectants eradicated these tumor cells just before or after extravasation from the lung capillary (at least after the arrest at the lung capillary).

An interesting point of this study is that MCP-1 gene transfection did not result in the inhibition of tumorigenicity or growth when inoculated into the s.c. space even in NK cell-intact SCID mice. The same phenomenon has been well documented by Hirose et al. (26) and ourselves (10, 11). Hirose et al. (26) demonstrated that MCP-1 gene transfection into Chinese hamster ovary cells had no effect on tumorigenicity in nude mice. We reported also that there was no effect of MCP-1 gene transfection on the tumorigenicity of human small cell...
lung cancer (H69/VP) cells in nude and SCID mice. As we proposed previously (20), antitumor effects by cytokine gene modification can be regulated differentially by various organ microenvironments (including the lung and skin). In fact, NK cells are found predominantly in the blood and spleen (27). Therefore, the microenvironments of the lungs and skin might differ especially in the accumulation or activation of NK cells induced by MCP-1.

In summary, MCP-1 gene transfection into human lung adenocarcinoma cells resulted in an inhibition of metastatic formation presumably via the activation of NK cells. Locally secreted MCP-1 can augment Ab-dependent cellular cytotoxicity reaction and the therapeutic efficacy of Ab through the accumulation of monocyte-macrophages into the tumors (11). Therefore, an approach to facilitate the recruitment and activation of immune-effector cells such as NK cells and monocyte-macrophages may be crucial for the development of a novel immunotherapy for lung cancer patients.

ACKNOWLEDGMENTS

We thank Drs. M. Miyasaka and T. Tanaka (Osaka University) for the gift of TM-β1 hybridoma and Dr. Y. Ohmoto and K. Murata (Otsuka Pharmaceuticals, Tokushima) for the purification of TM-β1 antibody and measurement of cytokines by ELISA. We also thank P. Kaneko for assistance with lymphocyte preparation.

REFERENCES

Natural Killer Cell-dependent Suppression of Systemic Spread of Human Lung Adenocarcinoma Cells by Monocyte Chemoattractant Protein-1 Gene Transfection in Severe Combined Immunodeficient Mice


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/60/24/7002

Cited articles
This article cites 25 articles, 11 of which you can access for free at:
http://cancerres.aacrjournals.org/content/60/24/7002.full#ref-list-1

Citing articles
This article has been cited by 6 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/60/24/7002.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/60/24/7002.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.